share_log
Moomoo 24/7 ·  Apr 16 16:05
Clearpoint Neuro Congratulates Its Partner Aviadobio on First Patient Treated in Its Aspire-Ftd Clinical Trial Evaluating Avb-101 for Frontotemporal Dementia With Grn Mutations
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment